Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI

Geert R. D’Haens, Anita Afzali, Silvio Danese, David T. Rubin, Remo Panaccione, Ailsa Hart, Nat A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Leonardo Salese, Jacqueline Yee, Wilbert van Duijnhoven, Elizabeth Merrall, Cristina Sotto, Qian Cao, Julián Panés, Flavio Steinwurz, Tadakazu Hisamatsu, Bruce E. Sands

Open source

DOI
10.1016/j.cgh.2026.10.011
Published
2026-10
Container
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cgh.2026.10.011,
  title = {Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 \& 3 and GRAVITI},
  author = {Geert R. D’Haens and Anita Afzali and Silvio Danese and David T. Rubin and Remo Panaccione and Ailsa Hart and Nat A. Terry and Mobolaji Olurinde and Rian Van Rampelbergh and Leonardo Salese and Jacqueline Yee and Wilbert van Duijnhoven and Elizabeth Merrall and Cristina Sotto and Qian Cao and Julián Panés and Flavio Steinwurz and Tadakazu Hisamatsu and Bruce E. Sands},
  year = {2026},
  journal = {Clinical Gastroenterology and Hepatology},
  doi = {10.1016/j.cgh.2026.10.011},
  url = {https://doi.org/10.1016/j.cgh.2026.10.011}
}

RIS

TY  - JOUR
TI  - Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI
AU  - Geert R. D’Haens
AU  - Anita Afzali
AU  - Silvio Danese
AU  - David T. Rubin
AU  - Remo Panaccione
AU  - Ailsa Hart
AU  - Nat A. Terry
AU  - Mobolaji Olurinde
AU  - Rian Van Rampelbergh
AU  - Leonardo Salese
AU  - Jacqueline Yee
AU  - Wilbert van Duijnhoven
AU  - Elizabeth Merrall
AU  - Cristina Sotto
AU  - Qian Cao
AU  - Julián Panés
AU  - Flavio Steinwurz
AU  - Tadakazu Hisamatsu
AU  - Bruce E. Sands
PY  - 2026
JO  - Clinical Gastroenterology and Hepatology
DO  - 10.1016/j.cgh.2026.10.011
UR  - https://doi.org/10.1016/j.cgh.2026.10.011
ER  - 

APA

D’Haens, G. R., Afzali, A., Danese, S., Rubin, D. T., Panaccione, R., Hart, A., Terry, N. A., Olurinde, M., Rampelbergh, R. V., Salese, L., Yee, J., Duijnhoven, W. V., Merrall, E., Sotto, C., Cao, Q., Panés, J., Steinwurz, F., Hisamatsu, T., & Sands, B. E. (2026). Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.10.011

Source records